Pfizer reported slightly higher first-quarter net profit as growth in drugs such as the blood thinner Eliquis offset declines in products with expiring patents. Net income was $3.1 billion, up 2.7 percent from the year-ago period. Revenues dipped 1.7 percent to $12.8 billion. Besides Eliquis, other drugs with growth included the breast cancer medicine Ibrance, the epilepsy drug Lyrica, the rheumatoid arthritis drug Xeljanz and the prostate cancer drug Xtandi, which Pfizer assumed with its 2016 acquisition of biotech company Medivation. But revenues in Pfizer's Essential Health business, which generally comprises older products, fell nine percent due to patent expirations for drugs including antidepressant Pristiq.
Copyright AFP (Agence France-Presse), 2017
AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.
Business Recorder shall not be responsible or held liable for any error of fact, opinion or recommendation and also for any loss, financial or otherwise, resulting from business or trade or speculation conducted, or investments made, on the basis of the information posted here. Nor shall Business Recorder be held liable for any actions taken in consequence." >Copyright Agence France-Presse, 2017